Semaglutide
Metabolic & Weight LossFDA ApprovedAlso known as: GLP-1S, GLP-1 Agonist, RC-1S, PEP-1S, ION-1S, Ion Peptide Semaglutide, GLP-1, Semaglutide, Sema
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin.
Reconstitution Calculator for Semaglutide
Pre-filled · 5mg vial · 250mcg dose
Overview
At A Glance
GLP-1 Receptor Agonism and cAMP Signaling…
Overview
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide (PMID: 35658024). Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.
Potential Research Fields
Chemical Information
IUPAC Name
N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-peptide
CAS Number
910463-68-2
Molecular Formula
C187H291N45O59
Molecular Mass
4113.58 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Personal or family history of medullary thyroid carcinoma (MTC). Multiple endocrine neoplasia syndrome type 2 (MEN 2). History of pancreatitis. Severe gastrointestinal disease. Type 1 diabetes. Pregnancy or breastfeeding. Eating disorders (may exacerbate restriction).
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$39.00
up to $174.99
$3.3000
7
13
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
RC-1S 30mg | vial | 30mg vial● In Stock | $174.99BEST | $5.833 | ||
 |
Pep-1S 5mg (Semaglutide) | vial | 5mg● In Stock | $59.99 | $11.998 | ||
|
|
Pep-1S 30mg (Semaglutide) | vial | 1 vial● In Stock | $174.99 | $5.833 | ||
 |
Semaglutide (ION-1S) 5mg | vial | 1 vial● In Stock | $39.00 | $7.800 | — | |
|
|
Semaglutide (ION-1S) 10mg | vial | 1 vial● In Stock | $55.00 | $5.500 | — | |
|
|
Semaglutide (ION-1S) 20mg | vial | 1 vial● Out of Stock | $69.00 | $3.450 | — | Sign in for stock alert |
|
|
Semaglutide (ION-1S) 30mg | vial | 1 vial● In Stock | $99.00 | $3.300 | — | |
 |
Semaglutide 5mg | vial | 5mg● In Stock | $94.99 | $18.998 | — | |
 |
Semaglutide (GLP-1 SM) 10mg Vial | vial | 1 vial● In Stock | $128.00 | $12.800 | ||
 |
Semaglutide 10mg | vial | 10mg● Out of Stock | $139.00 | $13.900 | Sign in for stock alert | |
 |
GLP-1S (Semaglutide) 2mg | vial | 2mg vial● In Stock | $69.99 | $34.995 | ||
|
|
GLP-1S (Semaglutide) 5mg | vial | 5mg vial● In Stock | $99.99 | $19.998 | ||
|
|
GLP-1S (Semaglutide) 10mg | vial | 10mg vial● In Stock | $159.99 | $15.999 |
Tracking since Mar 13, 2026 · 12 data points
Price History
5 data pointsVendors Selling Semaglutide
Ion Peptide
Optimum Formula
VANDL Labs
BioMyst Labs
Nova Peptides
Limitless Biochem EU
ResearchChemHQ
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAOD-9604
Metabolic & Weight LossPhase 3AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).
Cagrilintide
Metabolic & Weight LossPhase 3Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema.
HGH Fragment 176-191
Metabolic & Weight LossPhase 2HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity.
Retatrutide
Metabolic & Weight LossPhase 3Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly.
Tirzepatide
Metabolic & Weight LossFDA ApprovedTirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Semaglutide
Related Articles
All PostsAquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For
how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.
5/20/2026Retatrutide Protocol Guide 2026: Dosing, Titration, Side Effects, Week-by-Week
A standalone beginner protocol for retatrutide — Eli Lilly's triple GLP-1/GIP/glucagon agonist. Dose math, week-by-week titration, side-effect management, realistic expectations, and where to source research-grade material.
5/19/2026Semaglutide to Tirzepatide Switch Protocol: Dose Conversion + Week-by-Week Plan
Switching from Wegovy/Ozempic to Mounjaro/Zepbound is the most-asked transition in the GLP-1 community. Here is the dose-conversion math, the week-by-week protocol, and the side-effect pitfalls to plan for.
5/19/2026Research Score
3273 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification
Molecular Weight
4113.58 g/mol
Administration
Subcutaneous (weekly), Oral (daily)
CAS Number
910463-68-2
Trial Phase
FDA Approved
Safety Profile
Common Side Effects
- • Nausea (most common, affects 20-44% of patients, dose-dependent)
- • Vomiting (typically during dose titration, resolves with continued use)
- • Diarrhea and constipation
- • Abdominal pain and dyspepsia
- • Injection site reactions (subcutaneous formulation)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Semaglutide used for in research?
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185).
Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s.
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647).
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy.
Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide (PMID: 35658024).
Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.
What forms does Semaglutide come in?
Semaglutide is available in vial form.
How much does Semaglutide cost?
Prices start at $39.00 across 7 verified vendors.
How do I compare Semaglutide vendors?
Compare prices, payment methods, shipping, and COA scores across 7 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight LossPhase 3AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).
Cagrilintide
Metabolic & Weight LossPhase 3Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema.
HGH Fragment 176-191
Metabolic & Weight LossPhase 2HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity.
Retatrutide
Metabolic & Weight LossPhase 3Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly.
Tirzepatide
Metabolic & Weight LossFDA ApprovedTirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2.
Side-by-Side Comparisons
All ComparisonsCompare Semaglutide head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.